Annovis Bio (ANVS) Other Non-Current Liabilities (2019 - 2026)
Annovis Bio (ANVS) posted Other Non-Current Liabilities of $327000.0 for Q1 2026, down 45.04% sequentially from $595000.0 in Q4 2025, and up 82.68% YoY from $179000.0 in Q1 2025.
Annovis Bio (ANVS) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Annovis Bio has reported Other Non-Current Liabilities for 5 years, with the latest figure at $327000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 82.68% year-over-year to $327000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $327000.0 (up 82.68% YoY) and the FY2025 annual result came in at $595000.0, down 19.27% from the prior year.
- Other Non-Current Liabilities declined to $327000.0 in Q1 2026 per ANVS's latest filing, from $595000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $13.7 million in Q4 2023 and troughed at $179000.0 in Q1 2025.
- A 4-year average of $2.3 million and a median of $473750.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities tumbled 97.16% in 2025, then jumped 82.68% in 2026.
- Over 4 years, Other Non-Current Liabilities stood at $13.7 million in 2023, then tumbled by 94.61% to $737000.0 in 2024, then dropped by 19.27% to $595000.0 in 2025, then slumped by 45.04% to $327000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $327000.0, $595000.0, and $299000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 327,000.00 |
| Dec 31, 2025 | 595,000.00 |
| Sep 30, 2025 | 299,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 737,000.00 |
| Sep 30, 2024 | 442,500.00 |
| Jun 30, 2024 | 505,000.00 |
| Mar 31, 2024 | 6.30 Mn |
| Dec 31, 2023 | 13.68 Mn |
| Dec 31, 2019 | 106,000.00 |